Taipei Exchange - Delayed Quote TWD

SUNHAWK BIO (7759.TWO)

71.50
-23.20
(-24.50%)
At close: May 29 at 2:59:58 PM GMT+8
Loading Chart for 7759.TWO
  • Previous Close 94.70
  • Open 92.50
  • Bid 69.00 x --
  • Ask 71.50 x --
  • Day's Range 50.00 - 92.50
  • 52 Week Range 50.00 - 196.00
  • Volume 2,816,162
  • Avg. Volume 642,339
  • Market Cap (intraday) 5.01B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -1.40
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Sunhawk Vision Biotech, Inc. operates as a drug development company that develops microRNA therapeutic eye drops. The company was founded in 2019 and is based in Kaohsiung, Taiwan.

www.sunhawkvision.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 7759.TWO

View More

Performance Overview: 7759.TWO

Trailing total returns as of 5/29/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

7759.TWO
14.58%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
7.33%

1-Year Return

7759.TWO
14.58%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
1.46%

3-Year Return

7759.TWO
14.58%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
31.24%

5-Year Return

7759.TWO
14.58%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
95.09%

Compare To: 7759.TWO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 7759.TWO

View More

Valuation Measures

Annual
As of 5/29/2025
  • Market Cap

    5.09B

  • Enterprise Value

    4.90B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    17.20

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -20.08%

  • Return on Equity (ttm)

    -28.80%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -87.22M

  • Diluted EPS (ttm)

    -1.40

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    202.8M

  • Total Debt/Equity (mrq)

    3.20%

  • Levered Free Cash Flow (ttm)

    -72.86M

Research Analysis: 7759.TWO

View More

Company Insights: 7759.TWO

Research Reports: 7759.TWO

View More